Bi-weekly epirubicin, etoposide and low-dose dexamethasone for hormone-refractory prostate cancer.

Karel Odrazka; Miloslava Vaculikova; Jiri Petera; Petr Moravek; Petr Prosvic; Zdenek Zoul; Lubos Rydel; Milos Brodak; Zbynek Veselsky; Miroslav Louda

doi:10.1046/j.1442-2042.2003.00647.x

Bi-weekly epirubicin, etoposide and low-dose dexamethasone for hormone-refractory prostate cancer.

Identifier:nobleid.org/w1/20260515/F2F983DF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/F2F983DF.svg?ark=w1%2F20260515%2FF2F983DF)](https://nobleid.org/work/w1/20260515/F2F983DF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Bi-weekly epirubicin, etoposide and low-dose dexamethasone for hormone-refractory prostate cancer.

Identifier:nobleid.org/w1/20260515/F2F983DF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/F2F983DF.svg?ark=w1%2F20260515%2FF2F983DF)](https://nobleid.org/work/w1/20260515/F2F983DF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work